Enzalutamide
ANDA 216068, held by Sandoz. Enzalutamide.
- First approved: Apr 20, 2026
- Review: Standard
- Supplements approved: 0
- Complete response letters: 0
Approvals and New Uses
The original application and every efficacy supplement, newest first| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 20, 2026 | Original application | Approved |
Products
2 strengths and forms| Product | Active ingredient | Marketing |
|---|---|---|
| Enzalutamide40MG · tablet;oral | Enzalutamide | Rx |
| Enzalutamide80MG · tablet;oral | Enzalutamide | Rx |
Identifiers
- Application
- ANDA 216068
- Drugs@FDA
- Overview at FDA
- Company
- Sandoz
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters